×
About 204,575 results

ALLMedicine™ Breast Cancer Center

Research & Reviews  68,186 results

Beta 2 adrenergic receptor and mu opioid receptor interact to potentiate the aggressive...
https://doi.org/10.1186/s13058-022-01526-y 10.3322/caac.21590 10.1056/NEJMra1001389 10.1200/JCO.2007.14.4147 10.3816/CBC.2009.s.008 10.1200/JCO.2011.38.8595 10.1183/09031936.98.11010173 10.1016/S0140-6736(98)11392-2 10.1002/cncr.24561 10.18632/oncotarget.6479 10.4103/aja.aja_32_18 10.1007/s10549-011-1371-z 10.1007/s10549-019-05341-6 10.1016/S0398-7620(04)99022-0 10.1158/0008-5472.CAN-11-1610 10.1158/1940-6207.CAPR-14-0254 10.1158/0008-5472.CAN-11-3292 10.1038/s41386-018-0225-3 10.1139/O08-001 10.1007/s00210-011-0672-4 10.1371/journal.pone.0091577 10.1093/bja/aeu090 10.1213/ANE.0b013e31820568af 10.1016/j.tips.2011.02.010 10.1139/O08-001 10.3390/ijms21217968 10.3390/cancers13194858 10.3390/ijms20174137 10.1038/srep18198 10.1101/cshperspect.a006098 10.1038/nrc2761 10.1158/0008-5472.CAN-05-2474 10.1093/carcin/bgy135 10.1002/stem.2007 10.1016/j.canlet.2015.07.048 10.1530/ERC-14-0236 10.1155/2013/421821 10.1097/01.wnr.0000130433.90962.6e 10.1186/1475-2867-13-93 10.1016/j.molmed.2014.02.007 10.1186/bcr1515 10.1074/jbc.270.50.30093 10.1111/hpb.12442 10.1074/jbc.M802481200 10.1016/j.toxrep.2018.06.002 10.18632/oncotarget.8485 10.4149/neo_2009_02_108 10.1016/j.bja.2017.11.110 10.1172/JCI41407 10.1007/s00125-006-0484-0 10.1126/scisignal.2000647 10.1158/0008-5472.CAN-10-0522 10.1177/1758834012439738 10.4149/neo_2019_190110N34 10.31557/APJCP.2021.22.2.633 10.2147/OTT.S145780 10.1248/bpb.b17-00215
Breast Cancer Research : BCR; Rousseau B, Murugan S et. al.

May 16th, 2022 - Opioid and beta-adrenergic receptors are recently shown to cross talk via formation of receptor heterodimers to control the growth and proliferation of breast cancer cells. However, the underlying cell signaling mechanism remained unclear. To dete...

Pre-analytical processing protocol of breast biopsies affects multigene panel results.
https://doi.org/10.1111/iep.12444
International Journal of Experimental Pathology; Lima VR, da Costa Aguiar Alves B et. al.

May 16th, 2022 - The creation of multigene panels for prognostic and predictive purposes allows a more accurate indication of adjuvant chemotherapy for patients with breast cancer. In a previous study, we reproduced a multigene panel of 21 genes based on the comme...

see more →

Guidelines  146 results

Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: A...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029123
Current Oncology (Toronto, Ont.); Blanchette P, Sivajohanathan D et. al.

Apr 22nd, 2022 - The purpose of this guideline is to determine the clinical utility of multigene profiling assays in individuals with early-stage invasive breast cancer. This guideline was developed by Ontario Health (Cancer Care Ontario)'s Program in Evidence-Bas...

Guideline No. 422f: Menopause and Breast Cancer.
https://doi.org/10.1016/j.jogc.2021.09.011
Journal of Obstetrics and Gynaecology Canada : JOGC = Jou... Jacobson M, Mills K et. al.

Dec 14th, 2021 - Provide strategies for improving the care of perimenopausal and postmenopausal women based on the most recent published evidence. Perimenopausal and postmenopausal women. Target population will benefit from the most recent published scientific evi...

ACR Appropriateness Criteria® Supplemental Breast Cancer Screening Based on Breast Dens...
https://doi.org/10.1016/j.jacr.2021.09.002
Journal of the American College of Radiology : JACR; , Weinstein SP et. al.

Nov 20th, 2021 - Mammography remains the only validated screening tool for breast cancer, however, there are limitations to mammography. One of the limitations of mammography is the variable sensitivity based on breast density. Supplemental screening may be consid...

ACR Appropriateness Criteria® Transgender Breast Cancer Screening.
https://doi.org/10.1016/j.jacr.2021.09.005
Journal of the American College of Radiology : JACR; , Brown A et. al.

Nov 20th, 2021 - Breast cancer screening recommendations for transgender and gender nonconforming individuals are based on the sex assigned at birth, risk factors, and use of exogenous hormones. Insufficient evidence exists to determine whether transgender people ...

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients w...
https://doi.org/10.1016/j.annonc.2021.09.019
Annals of Oncology : Official Journal of the European Soc... Gennari A, André F et. al.

Oct 23rd, 2021 - ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.|2021|Gennari A,André F,Barrios CH,Cortés J,de Azambuja E,|diagnosis,therapy,

see more →

Drugs  539 results see all →

Clinicaltrials.gov  3,529 results

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT03822468

May 13th, 2022 - QT interval prolongation and neutropenia are considered to be important identified risks for ribociclib. The approved dosing regimen of ribociclib is 600 mg daily (QD) on a 3 weeks on/1 week off schedule. The purpose of the study is to explore whe...

Where Culture Meets Genetics: Exploring Latinas Causal Attributions of Breast and Colon Cancer and Models of Disease Inheritance
https://clinicaltrials.gov/ct2/show/NCT02767986

May 13th, 2022 - Research to understand the sources of health disparities has acknowledged that in addition to biomedical risk factors, culture plays an important role in differential health outcomes. Consequently, understanding cultural differences that may influ...

A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT03499899

May 13th, 2022 - This was an open-label, Phase II, randomized, multicenter study to assess the efficacy, safety, and pharmacokinetic characteristics of the following three combinations: LAG525 + spartalizumab (PDR001) (Arm 1), LAG525 + spartalizumab (PDR001) + car...

Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma
https://clinicaltrials.gov/ct2/show/NCT04941274

May 13th, 2022 - Background: Kaposi Sarcoma (KS) is a multicentric angioproliferative tumor, caused by Kaposi sarcoma-associated herpesvirus, that most frequently involves the skin, but may also involve lymph nodes, lungs, bone and gastrointestinal tract. It is mo...

RBX7455 Before Surgery for the Treatment of Operable Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT04139993

May 13th, 2022 - PRIMARY OBJECTIVES: I. To determine the safety and tolerability of microbiota-based formulation RBX7455 (RBX7455) given for at least 2 weeks and not more than 4 weeks prior to surgery. II. To evaluate intratumoral immunomodulatory effects, includi...

see more →

News  9,332 results

Nearly 234,000 Cancer Cases Predicted in Canada This Year
https://www.medscape.com/viewarticle/973931

May 13th, 2022 - About 233,900 new cancer cases and 85,100 cancer deaths are predicted to occur in Canada in 2022, according to new research. The most commonly diagnosed cancer overall will be lung cancer, followed by breast cancer for women and prostate cancer fo...

Risk of Dying From New Cancer Higher in Young Cancer Survivors
https://www.medscape.com/viewarticle/973908

May 12th, 2022 - Adolescent and young adult (AYA) cancer survivors face nearly a two-fold higher risk of dying from a new primary cancer compared with peers in the general population, new research shows. "These findings underscore the critical role of providing hi...

Uninformed Breast Cancer Patients Are Making Treatment Decisions
https://www.medscape.com/viewarticle/973783

May 11th, 2022 - Women with ductal carcinoma in situ (DCIS) breast cancer are generally uninformed about their diagnosis and are making uninformed treatment decisions, according to results of a study presented this month at ESMO Breast Cancer 2022, an annual meeti...

Twenty Years and Counting: Tamoxifen Benefit in Breast Cancer
https://www.medscape.com/viewarticle/973802

May 11th, 2022 - A study presented at ESMO Breast Cancer 2022 documents a "significant long-term benefit" among women with breast cancer who were treated with tamoxifen. The study was a secondary analysis of women with estrogen receptor (ER)-positive HER2-negative...

Uninformed breast cancer patients are making treatment decisions
https://www.mdedge.com/hematology-oncology/article/254508/metastatic-breast-cancer/uninformed-breast-cancer-patients-are
Diana Kwon

May 10th, 2022 - Women with ductal carcinoma in situ (DCIS) breast cancer are generally uninformed about their diagnosis and are making uninformed treatment decisions, according to results of a study presented this month at ESMO Breast Cancer 2022, an annual meeti.

see more →

Patient Education  98 results see all →